Zenas BioPharma (ZBIO) Fundamental Analysis: Revenue, Earnings & Valuation

3.47 / 10

Netural

ZBIO's fundamental score is 3.5/10, reflecting challenging quality. Key bullish factors include a healthy interest-coverage ratio (EBIT/Interest expense = 15.48) and positive Profit-MV. However, headwinds such as high Days Sales Outstanding (72.55) and an elevated PB-ROE (1.83) temper the outlook. The company shows strong revenue growth (Operating revenue YoY +92.66%, Total operating revenue YoY +78.47%), but these gains are offset by inventory and profitability concerns, resulting in a net neutral fundamental stance.

Analysis Checks(7/10)

Revenue-MV

Value-0.26

Score1/3

Weight7.78%

1M Return4.24%

Total operating revenue (YoY growth rate %)

Value78.47

Score2/3

Weight1.66%

1M Return1.11%

Days sales outstanding

Value72.55

Score1/3

Weight-2.13%

1M Return-1.57%

Profit-MV

Value0.46

Score2/3

Weight15.46%

1M Return8.45%

Net income-Revenue

Value-0.17

Score2/3

Weight15.47%

1M Return8.45%

PB-ROE

Value1.83

Score1/3

Weight18.82%

1M Return9.57%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.48

Score2/3

Weight-1.55%

1M Return-1.11%

Operating revenue (YoY growth rate %)

Value92.66

Score2/3

Weight0.64%

1M Return0.43%

Asset-MV

Value-0.50

Score3/3

Weight28.66%

1M Return13.15%

Cash-MV

Value-0.07

Score2/3

Weight15.20%

1M Return8.41%

Is ZBIO undervalued or overvalued?

ZBIO scores 3.47/10 on fundamentals and holds a Fair valuation at present. Backed by its -53.96% ROE, -1265.99% net margin, -6.59 P/E ratio, 5.94 P/B ratio, and 130.47% earnings growth, these metrics solidify its Netural investment rating.